About this trial
This prospective observational study aims to evaluate the validity of ultrasonographic muscle measurements in patients with inflammatory bowel disease (IBD). Sarcopenia is commonly assessed using computed tomography (CT)-based skeletal muscle area measurements at the L3 vertebral level, which are considered a gold standard method. However, CT is not always feasible due to radiation exposure and accessibility limitations.
In this study, muscle strength will be assessed using handgrip dynamometry, and muscle mass will be evaluated using ultrasonography of selected skeletal muscles. In patients with available recent abdominal CT imaging, L3 skeletal muscle area will be recorded. The primary objective is to compare ultrasonographic muscle measurements with CT-based assessments and to evaluate the agreement between these methods.
This study aims to determine whether ultrasonography can serve as a practical and reliable alternative tool for muscle mass evaluation in patients with IBD.
Eligibility criteria
Qualifiers
Age ≥18 years
Established diagnosis of inflammatory bowel disease (ICD-10: K50.* Crohn's disease, K51.* ulcerative colitis)
Ability to provide written informed consent
Ability to undergo ultrasonographic muscle assessment and handgrip strength testing
Disqualifiers
Known neuromuscular disorders or primary muscle diseases
Major orthopedic conditions affecting muscle strength assessment
Pregnancy
Abdominal wall defects or conditions interfering with ultrasound assessment
Trial design
Treatments tested in this trial
- Muscle Ultrasonography